Document is current
Any future updates will be listed below
-
Authors
Schnitzer, Thomas J. http://orcid.org/0000-0002-4048-5431
Conaghan, Philip G.
Berenbaum, Francis
Abraham, Lucy
Cappelleri, Joseph C.
Bushmakin, Andrew G.
Viktrup, Lars
Yang, Ruoyong
Brown, Mark T.
-
Funding
Funding for this research was provided by:
Pfizer (NA)
Eli Lilly and Company (NA)
- License Information
-
More Information
Article History
Received: 27 March 2023
Accepted: 14 February 2024
First Online: 22 April 2024
Declarations
:
: This study derived data from clinical trials for which the primary results have already been published. Details on ethical approval of the studies can be found in the primary publications.
: Not applicable.
: Thomas J. Schnitzer has received grants from Kolon TissueGene, Pfizer, Regeneron, Galapagos, Lilly, Paradigm, TLC, Ltd, Anika, Novartis; personal fees and non-financial support from Pfizer, Lilly, Regeneron, Aptinyx, Calibr, GSK, Astra-Zeneca, Genascence, Biosplice, Xalud, IBSA, IQVIA, and Vertex. Philip G Conaghan has received consulting or speaker fees from AbbVie, AstraZeneca, Eli Lilly, Galapagos, GlaxoSmithKline, Grunenthal, Janssen, Levicept, Merck, Novartis, Pfizer, Regeneron, Stryker, and UCB. Francis Berenbaum has received consulting or speaker fees from AstraZeneca, Boehringer Ingelheim, Bone Therapeutics, Cellprothera, Galapagos, Gilead, Grunenthal, GSK, Eli Lilly, MerckSerono, Nordic Bioscience, Novartis, Pfizer, Sanofi, Servier, Peptinov, Viatris, Aché Laboratories; and is a sharholderof 4Moving Biotech and 4P Pharma. Lucy Abraham, Joseph C. Cappelleri, Andrew Bushmakin, and Ruoyong Yang, are full-time employees of, and own stock/options in, Pfizer. Mark Brown was a full-time employee of Pfizer at the time the research was conducted. Lars Viktrup is a full-time employee of, and owns stocks in, Eli Lilly and Company.
